Google Ads for Peptide Brands in 2026: An Ever-Evolving Policy Landscape

Google maintains an explicit list of prohibited substances under its Healthcare and Medicines policy, which includes most controlled substances and a specific list of restricted peptides. Selective Androgen Receptor Modulators (SARMs), some GH-related compounds, and various banned-substance categories are non-negotiable — no peptide brand should attempt to advertise these products on Google Ads. Attempting to do so is the fastest path to permanent account-level suspension and trying to recover from a SARM-related suspension is essentially impossible.

The much larger grey zone covers the RUO peptide products that make up the bulk of typical peptide brand catalogues — research peptides, peptide reference standards, and similar. None of these are explicitly prohibited. None are explicitly permitted. They live in policy-by-context territory: the same product page can pass review or fail review depending on how the page is framed, what claims appear elsewhere on the site, what the ad creative says, and what the landing page looks like the day a reviewer happens to look at it.

The grey zone is where peptide marketing on Google actually happens. Operating successfully inside it requires a stable framework for what to include, what to exclude, and how to structure every layer of the funnel (ad copy, landing page, site, claims language, reviews, third-party signals) to land consistently on the approved side of the line. That framework takes years to develop and is the thing peptide-specialist agencies actually sell.

Google Shopping has tighter policy enforcement than any other Google Ads surface. Merchant Center accounts that traffic peptide products are reviewed against a different and stricter standard than Search ads — partly because Shopping is more visual and partly because the European Union has applied specific regulatory pressure to Shopping under the Digital Services Act.

Practical consequences: most peptide brands cannot run Google Shopping at all on their full catalogue. The Merchant Center will reject products by feed, suspend the account if multiple violations accrue, or quietly suppress products from results. The brands that do manage to run Shopping typically do so on a deliberately narrow product feed — peptide-adjacent products that read as supplements, accessories, or research tools rather than the core RUO inventory. The trade-off is that the products driving Shopping are not the products driving brand revenue.

There are advanced strategies for Shopping that involve segmented Merchant Centers, careful feed engineering, and disciplined separation between the e-commerce store and the products surfaced to Shopping. We have implemented variants of this approach for several brands, but the realistic expectation for any peptide brand entering Google Ads in 2026 is that Shopping will be a small share of channel revenue and Search will carry the load.

Search is the most reliable Google surface for peptide brands. Brand-defense keywords convert at very high rates. Non-brand category keywords (research peptides, reference peptides, specific compound names) convert at workable rates with disciplined landing pages. The constraint on Search is keyword approval — many specific peptide names are flagged as restricted drug terms and require either alternate keyword spellings or RSA copy that avoids triggering automated filters. A peptide-savvy paid search team has a working library of keyword variants that pass review.

Display is generally a poor fit for peptide brands. The audience targeting limits, creative restrictions, and brand-safety adjacencies make Display a low-ROI channel for almost every peptide brand we manage. The exception is remarketing on Display, which can work when configured carefully and segmented away from cold prospecting.

Performance Max is unpredictable. The same campaign that delivers strong returns for three weeks can have its budget shifted by Google's automation into asset groups that suddenly trigger policy reviews. We have largely moved away from broad Performance Max campaigns for peptide brands in favor of tightly scoped Search and Remarketing campaigns where the team controls more of the targeting and creative surface. Brands that insist on running Performance Max should at minimum exclude their main RUO product pages from the campaign feed and run it on adjacent SKUs only.

Every peptide brand running Google Ads will eventually experience an account suspension. The question is not whether but how often and how recoverable. The categories of suspension we see most often: Compromised Account suspensions (often related to billing or login anomalies), Suspicious Payment Activity, Circumventing Systems, Unacceptable Business Practices, and Misrepresentation. Each has different recovery paths.

The fastest recoveries come from suspensions that have a clear factual basis to dispute — a payment method flagged incorrectly, a circumvention claim that does not actually apply, a misrepresentation claim about a single ad that can be edited and resubmitted. These can resolve in 2–5 business days through the standard appeals process if the appeal is written precisely and the supporting documentation is in order.

The hardest recoveries come from Unacceptable Business Practices suspensions, which Google's policy team interprets very broadly. These are the suspensions where a peptide-specialist team's relationships matter most. Direct escalation to a Google rep with vertical familiarity, accompanied by a clear narrative about the brand's compliance posture, often unblocks accounts that the standard appeals process would not. Without that relationship layer, recovery often means starting from scratch with a fresh account — which itself requires careful setup to avoid being flagged as a circumvention attempt.

Most peptide brands obsess over what their ads say and under-invest in what their landing pages say. Google's policy enforcement weighs the landing page experience more heavily than the ad copy in almost every category — and especially in healthcare-adjacent ones. An ad with conservative copy that points to a landing page making aggressive claims will fail. An ad with mildly aggressive copy that points to a landing page with careful framing will often pass.

Practical implication: the landing page is where peptide brands win or lose Google Ads. The page needs to frame product clearly within RUO context, include the right compliance language, avoid prohibited claims, demonstrate third-party testing transparency, and structure conversion architecture (CTAs, trust signals, product details) in a way that does not look like it is trying to skirt policy. Most peptide brand PDPs were built without these considerations and need rebuilding before paid traffic can be sent to them at scale.

We routinely advise new peptide clients to delay their first Google Ads launch by two to four weeks so the landing-page experience can be rebuilt for compliance. The delayed launch produces materially better economics and a much lower suspension rate than launching on a stock storefront.

Many peptide brands eventually consider running multiple Google Ads accounts to mitigate suspension risk. Google's Circumventing Systems policy explicitly prohibits this when it is done to evade enforcement. The line between legitimate multi-account structure and prohibited circumvention is narrower than most brands realize and operationally difficult to walk.

Legitimate multi-account structure looks like separate MCC (Manager Account) trees for distinct legal entities, distinct payment methods, distinct billing addresses, and distinct landing-page domains — typically when a brand operates multiple genuinely separate products or business lines. Prohibited circumvention looks like running the same store under multiple accounts with cosmetic differences to insulate against suspension. Google's detection of the latter is strong.

Our standard advice is to run a single primary account with strong compliance discipline rather than fragment across multiple accounts of questionable status. A clean, well-managed single account, augmented by a fully separate sister account on a different domain selling a genuinely different SKU mix, produces a stronger long-term posture than a fragmented multi-account play.

Most peptide brands never get a dedicated Google rep, because spend thresholds for rep assignment are high and peptide accounts tend to fall in and out of qualifying tiers as suspensions and recoveries reset the accumulated spend signal. This means most peptide brands experience Google Ads entirely through the self-service interface — and the self-service interface treats every account identically, with no human escalation path when things go wrong.

Peptide-specialist agencies maintain rep relationships across many accounts simultaneously, which gives them aggregate spend signals that qualify for rep assignment and accumulated relationship capital that pays off when escalations matter. When an account is suspended improperly, a rep who already knows the agency's portfolio can move a case forward in hours that would otherwise take weeks. When a new account is launching, a rep can flag policy considerations before money is spent on creative that would have been rejected.

This is a meaningful share of the value a peptide-specialist agency delivers. It is also the part of the value proposition that is invisible to most founders evaluating agencies — because the deliverable is not a report or a creative, it is a relationship that quietly accelerates everything else.

Our Google Ads engagements for peptide brands typically combine: structured Search campaigns on brand and category terms with carefully built RSA copy, a tight Remarketing layer with carefully segmented audiences, selective Performance Max where adjacent SKUs justify it, account-level compliance hygiene that keeps the account in good standing, landing-page audits and rebuilds where existing PDPs cannot support paid traffic, and an active escalation channel to Google reps for the inevitable policy events.

Reporting is built around blended ROAS, true new-customer CAC, and channel-specific contribution rather than just last-click attribution. Google's reporting interface dramatically over-credits Search in some configurations and under-credits it in others. The number that actually matters is the relationship between Google spend and incremental revenue, and we measure that with disciplined holdout testing rather than relying on platform-reported numbers alone.

If your Google Ads account has been suspended or you are launching paid search for the first time, this is the work we handle for every client. Book a call and we will walk through what your specific situation needs.

The peptide brands that succeed on Google in 2026 are not the ones with the biggest budgets. They are the ones with the most disciplined compliance posture, the cleanest landing-page architecture, and the relationships to move escalations through quickly when they happen. Budget without discipline produces a stream of suspensions. Discipline with modest budget produces compounding returns.

Treat Google Ads as an infrastructure investment rather than a tap you turn on. Build the compliance layer, build the landing pages, build the rep relationships, and the paid spend will follow.